Duncan K Topliss

Prof. Duncan K Topliss


Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
KRKathlyn J. Ronaldson
Kathlyn J. Ronaldson
PFPaul B Fitzgerald
Paul B Fitzgerald
ATAndrew J. Taylor
Andrew J. Taylor
DTDuncan K Topliss
Duncan K Topliss
JMJohn McNeil
John McNeil
Objective: To develop an evidence-based monitoring protocol for clozapine-induced myocarditis. Methods: Potential cases of clozapine-related myocarditis occurring between January 1994 and January 2009 and a comparative group of patients taking clozapine for at least 45 days without cardiac disease were documented from the patients’ medical records. Results: A total of 75 cases and 94 controls were included. Nine cases died. The time to onset was 10–33 days with 83% of cases developing between days 14 and 21 inclusive. At least twice the upper limit of normal troponin was found in 90% of cases, but 5 cases had C-reactive protein more than 100 mg/L and left ventricular impairment by echocardiography without a clinically significant rise in troponin. The proposed monitoring protocol recommends obtaining baseline troponin I/T, C-reactive protein and echocardiography, and monitoring troponin and C-reactive protein on days 7, 14, 21 and 28. Mild elevation in troponin or C-reactive protein, persistent abnormally high heart rate or signs or symptoms consistent with infective illness should be followed by daily troponin and C-reactive protein investigation until features resolve. Cessation of clozapine is advised if troponin is more than twice the upper limit of normal or C-reactive protein is over 100 mg/L. Combining these two parameters has an estimated sensitivity for symptomatic clozapine-induced myocarditis of 100%. The sensitivity for asymptomatic disease is unknown. Conclusion: This protocol recommends active monitoring for 4 weeks, relying predominantly on troponin and C-reactive protein results. It encourages continuation of clozapine in the presence of mild illness, but defines a threshold for cessation.

24 April 2015 in Cancer
Verified
Journal Article
Open access
PDF file
MCMaria E. Cabanillas
Maria E. Cabanillas
MSMartin Schlumberger
Martin Schlumberger
Barbara Maria JarzabBarbara Maria Jarzab
Barbara Maria Jarzab
RMRenato G. Martins
Renato G. Martins
FPFurio Pacini
Furio Pacini
DBDouglas W. Ball
Douglas W. Ball
BACKGROUND: Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1‐VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1‐FGFR4), platelet‐derived growth factor receptor α (PDGFRα), ret proto‐oncogene (RET), and v‐kit Hardy‐Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine‐refractory, differentiated thyroid cancer (RR‐DTC).METHODS: Fifty‐eight patients with RR‐DTC who had disease progression during the previous 12 months received lenvatinib 24 mg once daily in 28‐day cycles until disease progression, unmanageable toxicity, withdrawal, or death. Previous VEGFR‐targeted therapy was permitted. The primary endpoint was the objective response rate (ORR) based on independent imaging review. Secondary endpoints included progression‐free survival (PFS) and safety. Serum levels of 51 circulating cytokines and angiogenic factors also were assessed.RESULTS: After ≥14 months of follow‐up, patients had an ORR of 50% (95% confidence interval [CI], 37%‐63%) with only partial responses reported. The median time to response was 3.6 months, the median response duration was 12.7 months, and the median PFS was 12.6 months (95% CI, 9.9‐16.1 months). The ORR for patients who had received previous VEGF therapy (n = 17) was 59% (95% CI, 33%‐82%). Lower baseline levels of angiopoietin‐2 were suggestive of tumor response and longer PFS. Grade 3 and 4 treatment‐emergent adverse events, regardless of their relation to treatment, occurred in 72% of patients and most frequently included weight loss (12%), hypertension (10%), proteinuria (10%), and diarrhea (10%).CONCLUSIONS: In patients with and without prior exposure to VEGF therapy, the encouraging response rates, median time to response, and PFS for lenvatinib have prompted further investigation in a phase 3 trial. Cancer 2015;121:2749‐2756. © 2015 American Cancer Society

1 November 2012 in Schizophrenia Research
Verified
Journal Article
Closed access
KRKathlyn J. Ronaldson
Kathlyn J. Ronaldson
PFPaul B Fitzgerald
Paul B Fitzgerald
ATAndrew J. Taylor
Andrew J. Taylor
DTDuncan K Topliss
Duncan K Topliss
RWRory Wolfe
Rory Wolfe
JMJohn McNeil
John McNeil

18 December 2014 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MHMarkus Herrmann
Markus Herrmann
DSDavid R. Sullivan
David R. Sullivan
AVAnne-Sophie Veillard
Anne-Sophie Veillard
TMThomas McCorquodale
Thomas McCorquodale
ISIsabella R. Straub
Isabella R. Straub
AKAnthony C. Keech
Anthony C. Keech
OBJECTIVE People with diabetes frequently develop vascular disease. We investigated the relationship between blood 25-hydroxyvitamin D (25OH-D) concentration and vascular disease risk in type 2 diabetes. RESEARCH DESIGN AND METHODS The relationships between blood 25OH-D concentration at baseline and the incidence of macrovascular (including myocardial infarction and stroke) and microvascular (retinopathy, nephropathy, neuropathy, and amputation) disease were analyzed with Cox proportional hazards models and logistic regression in an observational study of patients in the 5-year Fenofibrate Intervention and Event Lowering in Diabetes trial. RESULTS A total of 50% of the patients had low vitamin D concentrations, as indicated by median blood 25OH-D concentration of 49 nmol/L. These patients with a blood 25OH-D concentration <50 nmol/L had a higher cumulative incidence of macrovascular and microvascular events than those with levels ≥50 nmol/L. Multivariate analysis, stratified by treatment and adjusted for relevant confounders, identified blood 25OH-D concentration as an independent predictor of macrovascular events. A 50 nmol/L difference in blood 25OH-D concentration was associated with a 23% (P = 0.007) change in risk of macrovascular complications during the study, and further adjustments for seasonality, hs-CRP, and physical activity level had little impact. The unadjusted risk of microvascular complications was 18% (P = 0.006) higher during the study, though the excess risk declined to 11–14% and lost significance with adjustment for HbA1c, seasonality, or physical activity. CONCLUSIONS Low blood 25OH-D concentrations are associated with an increased risk of macrovascular and microvascular disease events in type 2 diabetes. However, a causal link remains to be demonstrated.

1 April 1986 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
PHPeter S Hamblin
Peter S Hamblin
SDStephanie A. Dyer
Stephanie A. Dyer
VMVirginia S. Mohr
Virginia S. Mohr
BGBrenda A. LE Grand
Brenda A. LE Grand
CLChen-Fee Lim
Chen-Fee Lim
JSJan R. Stockigt
Jan R. Stockigt
In a prospective study of critically ill hypothyroxinemic patients, we assessed the relationship between serum TSH and T4 during the return of serum T4 normal during recovery. In this longitudinal study of 60 patients with a variety of critical illnesses, including burns, septicemia, and acute renal failure, serum T4 fell to less than 2.7 μg/dl (35 nmol/liter) in 24 patients, of whom 14 survived with return of T4 to normal. A rise in total T4 of more than 1.9 μg/dl (25 nmol/liter) within 96 h occurred 13 times in 10 patients, while 4 patients had slower increases in T4. All 13 episodes of rapid T4 rise [1.7 ± 0.8 (± SD) to 5.6 ± 2.1 μg/dl] were associated with a marked increase in serum TSH (1.1 ± 0.8 to 7.0 ± 5.2 mU/liter), and TSH was transiently above normal during 8 episodes of T4 recovery. In the 6 episodes with sampling less than 6 h apart, the TSH rise consistently preceded the T4 rise. In the 4 patients who received dopamine, TSH and T4 remained low until cessation of therapy. During the TSH rise, only minor changes, which could not account for the increase in total T4, occurred in T4-binding globulin (12.9 ± 3.3 to 14. 8 ± 3.3 mg/liter), prealbumin (208 ± 73 to 234 ± 82 mg/liter), and albumin (28.3 ± 2.9 to 31.9 ± 2.9 g/liter). Mean free T4 increased (0.60 ± 0.34 to 1.45 ± 0.56 ng/dl), as did total T3 (16 ± 14 to 76 ± 44 ng/dl), during the phase of TSH rise, suggesting that the increase in TSH was not simply a consequence of diminished negative feedback due to increased plasma binding. The very close and consistent temporal relationship between TSH and T4 during the recovery phase suggests that TSH may have an essential role in the return of T4 to normal during recovery from critical nonthyroidal illness

9 March 2010 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
KRKathlyn J. Ronaldson
Kathlyn J. Ronaldson
ATAndrew J. Taylor
Andrew J. Taylor
PFPaul B Fitzgerald
Paul B Fitzgerald
DTDuncan K Topliss
Duncan K Topliss
MEMaros Elsik
Maros Elsik
JMJohn McNeil
John McNeil
To analyze cases of clozapine-induced myocarditis for clinical and diagnostic trends. A case definition was developed by a multidisciplinary group using reports of myocarditis with clozapine submitted to the Australian Therapeutic Goods Administration. The definition uses for diagnosis either histology or the combination of new signs of cardiac dysfunction combined with a cardiac-specific diagnostic parameter occurring within 45 days of starting clozapine. Potential cases of clozapine-related myocarditis occurring between January 1993 and September 2008 and a comparative group of long-term clozapine users were documented from the patients' medical records. Thirty-eight of 59 reviewed cases met the case definition. Three patients died, and the diagnosis for these was confirmed on cardiac histology. Nearly all of the remaining patients had persistent tachycardia and elevated troponin level. The time to onset was 14-22 days in all except 2 patients. Of the patients who survived, 66% (23 cases) had eosinophilia occurring 0-7 days (mean, 4.0) after the peak in troponin. C-reactive protein (CRP) level was elevated to above 100 mg/L (952 nmol/L) in 79% (23 cases), and some had elevated levels of CRP when troponin level was still normal. None of the control group (47 patients) met the case definition. Eosinophil counts should not be relied on for diagnosis of clozapine-related myocarditis, but elevated CRP may be an early indicator of developing myocarditis. Patients starting clozapine should be actively monitored for myocarditis during the first 4 weeks, with extra care taken during week 3.